Evidence map›Paper›PMID 38672694›Full record

ArticleCancers2024

RETRACTED: Lai et al. MicroRNA-21 Plays Multiple Oncometabolic Roles in the Process of NAFLD-Related Hepatocellular Carcinoma via PI3K/AKT, TGF-β, and STAT3 Signaling.

Chi-Yu Lai, Kun-Yun Yeh, Chiu-Ya Lin, Yang-Wen Hsieh, Hsin-Hung Lai, Jim-Ray Chen, Chia-Chun Hsu, Guor Mour Her

RetractedOpen access · goldAbstract readRetraction Notice
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. MicroRNAs and Nonalcoholic Steatohepatitis: A Review.International journal of molecular sciences · 2023
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Chi-Yu LaiDepartment of Bioscience and Biotechnology, National Taiwan Ocean University, Keelung 202, Taiwan.ORCID 0000-0003-0755-8018
Kun-Yun YehDivision of Hemato-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung 204, Taiwan.ORCID 0000-0001-5572-7897
Chiu-Ya LinDepartment of Bioscience and Biotechnology, National Taiwan Ocean University, Keelung 202, Taiwan.
Yang-Wen HsiehDepartment of Bioscience and Biotechnology, National Taiwan Ocean University, Keelung 202, Taiwan.
Hsin-Hung LaiInstitute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
Jim-Ray ChenDepartment of Pathology, Chang Gung Memorial Hospital, Keelung 204, Taiwan.
Chia-Chun HsuDepartment of Radiology, Buddhist Tzu Chi General Hospital, Taichung Branch, Taichung 427, Taiwan.
Guor Mour HerInstitute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.ORCID 0000-0002-5478-3878
National Yang Ming Chiao Tung University · TWKeelung Chang Gung Memorial Hospital · TWTzu Chi University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The

Identifiers

PMID38672694
PMCPMC11049415
OpenAlexW4395000278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.